Front Row lecture series
Expanding the drug target universe
Benjamin Cravatt, PhD
Professor, Norton B. Gilula Chair in Biology and Chemistry, Department of Chemistry
Wednesday, September 17, 2025
4:00 p.m. PT | 7:00 p.m. ET
There are countless proteins that play critical roles in disease, yet they remain challenging to target with therapeutics. In this free Front Row lecture, professor Benjamin Cravatt explained how his large-scale protein profiling research and innovative chemical technologies are helping identify novel drugs for therapeutic targets previously deemed ‘undruggable.’ Cravatt’s translational work, which is at the intersection of chemistry and biology, has also led to the formation of multiple local biotechnology companies that collectively employ hundreds of scientists who are developing first-in-class candidate medicines for diverse diseases ranging from cancer to neurological disorders.
Presented: September 17, 2025
Presentation slides
Key Takeaways
There are countless proteins that play critical roles in disease, yet they remain challenging to target with therapeutics. In this free Front Row lecture, professor Benjamin Cravatt explained how his large-scale protein profiling research and innovative chemical technologies are helping identify novel drugs for therapeutic targets previously deemed ‘undruggable.’ Cravatt’s translational work, which is at the intersection of chemistry and biology, has also led to the formation of multiple local biotechnology companies that collectively employ hundreds of scientists who are developing first-in-class candidate medicines for diverse diseases ranging from cancer to neurological disorders.
Speaker Spotlight
Scripps Research scientists discover chemical probes for previously “undruggable” cancer target
Scientists uncover how small molecules interact with a cancer-related protein called FOXA1 and identify a crucial binding site on its surface.
Learn More
Seeing double: Designing drugs that target “twin” cancer proteins
Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its “twin,” or paralog.
Learn More
Benjamin Cravatt awarded Tetrahedron Prize for Creativity
Benjamin Cravatt, the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research, will receive the 2025 Tetrahedron Prize for Creativity in Bioorganic and Medicinal Chemistry.
Learn More
Professor Benjamin Cravatt and physician-scientist Lou Lange join Scripps Research Board of Directors
Scripps Research has added Benjamin Cravatt, PhD, professor of Chemistry and the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research, and Lou Lange, MD, PhD, physician-scientist and general partner with Asset Management Ventures, to its Board of Directors.
Learn More